A Case Report on Hypomethylating Agent-Induced Cardiomyopathy
In Myelodysplastic syndrome, hypomethylating agents, 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine), which work by inhibiting DNA methyltransferase, have been approved (MDS). Cytopenias, nausea, pain, and local reactions in injection sites are the most common side effects of hypomethylating agents. Toxicity associated with
Read More